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Abstract: Nonalcoholic fatty liver disease (NAFLD) encompasses a broad spectrum of pathological
hepatic conditions ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), which
may predispose to liver cirrhosis and hepatocellular carcinoma (HCC). Due to the epidemic obesity,
NAFLD is representing a global health issue and the leading cause of liver damage worldwide. The
pathogenesis of NAFLD is closely related to insulin resistance (IR), adiposity and physical inactivity
as well as genetic and epigenetic factors corroborate to the development and progression of hepatic
steatosis and liver injury. Emerging evidence has outlined the implication of gut microbiota and
gut-derived endotoxins as actively contributors to NAFLD pathophysiology probably due to the tight
anatomo-functional crosstalk between the gut and the liver. Obesity, nutrition and environmental
factors might alter intestinal permeability producing a favorable micro-environment for bacterial
overgrowth, mucosal inflammation and translocation of both invasive pathogens and harmful
byproducts, which, in turn, influence hepatic fat composition and exacerbated pro-inflammatory
and fibrotic processes. To date, no therapeutic interventions are available for NAFLD prevention
and management, except for modifications in lifestyle, diet and physical exercise even though they
show discouraging results due to the poor compliance of patients. The premise of this review is to
discuss the role of gut–liver axis in NAFLD and emphasize the beneficial effects of probiotics on gut
microbiota composition as a novel attractive therapeutic strategy to introduce in clinical practice.
Keywords: nonalcoholic fatty liver disease; gut microbiota; gut–liver axis; leaky gut; intestinal
permeability; tight junctions; endotoxemia; probiotics
1. Introduction
The global burden of nonalcoholic fatty liver disease (NAFLD) as the leading cause of chronic
liver disorders represents a major concern for public health. It encompasses a wide spectrum of hepatic
conditions ranging from simple steatosis, a benign manifestation characterized by lipid accumulation
exceeding 5% of liver weight excluding other etiological causes, to a more severe form, such as
nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis and hepatocellular carcinoma (HCC) [1,2].
NAFLD is broadly spread in Western countries, affecting between 20% and 40% of the adult population,
possibly due to the epidemics of obesity and type 2 diabetes mellitus (T2DM) [3].
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The pathogenesis of NAFLD is closely intertwined with increased adiposity, insulin resistance
(IR) and dyslipidemia [4]. Dietary factors such as excessive caloric intake, fructose and physical
inactivity represent other risk factors for this condition [5]. Furthermore, the inter-individual
variability in NAFLD phenotype may be at least in part attributed to genetics. Single nucleotide
polymorphisms (SNPs) in proteins regulating hepatocellular lipid handling, including Patatin-like
Phospholipase Domain-containing 3 (PNPLA3), Transmembrane 6 Superfamily Member 2 (TM6SF2)
and Membrane Bound O-acyltransferase Domain-containing 7 (MBOAT7), have been associated to
NAFLD predisposition and progression towards NASH and fibrosis [6]. However, less than 10% of
inherited variability is explained by these common variants. Many of the phenotypic differences may
also result from gene-environment interactions, referred to as epigenetics, a hereditable but reversible
phenomenon that affects gene expression without modifying DNA sequence, such as alterations of
DNA nucleotides (i.e., methylation), modifications of histones and regulation of transcription by
altering mRNA stability through small RNA molecules such as microRNAs (miRNAs) [7,8].
Therefore, as a complex disease, the pathophysiology of NAFLD is not completely elucidated and
may be simultaneously influenced by multiple parallel hits including IR, oxidative stress, inflammation,
epigenetic modifiers and many others. Among the plethora of risk factors, recent evidence has
pointed out to the role of gut microbiota and its metabolites in the pathophysiology of alcoholic
fatty liver disease (ALD) and NAFLD [9,10]. Indeed, qualitative and quantitative changes in gut
microbiome composition (referred to as ‘dysbiosis’) and derangement in the gut–liver axis that favors
viable gut-derived bacteria and endotoxins translocation into the bloodstream have emerged to be
independently associated to the development of NAFLD and its progression to NASH and HCC.
Thus, species-specific microbial communities might profile NAFLD stages [11–15], possibly enabling
the intestinal flora modulation a diagnostic strategy and an eventual therapeutic intervention in the
personalized NAFLD management. Currently, liver biopsy remains the gold standard procedure for
diagnosis of NASH and no medications have been approved for the treatment of NAFLD patients
except for modifications in lifestyle, nutrition and physical exercise and weight loss [16,17].
For this reason, this review aimed to focus on the relevance of gut microbiota dysregulation in
the development and progression of NAFLD and its pivotal role as non-invasive biomarkers and
therapeutic target in the tailored NAFLD clinical management. Therefore, we will highlight the use
of probiotics, emphasizing their beneficial effects on dysbiosis as a potential therapeutic approach to
introduce in clinical practice.
2. Insight into the Gut Microbiota in NAFLD
The human gastrointestinal lumen is the physiological habitat for more than 100 trillion
microorganisms, which is approximately ten-times the number of somatic cells in the human body,
hosting a wide variety of microbial species (archaea, fungi, yeast, bacteria and viruses) [16]. The
gut microflora is a large reservoir of commensal microbes that live synergistically with the host and
provide biological and metabolic functions benefiting the host. It includes more than 160 different
bacterial species, including anaerobes and they carry more than three million unique genes [17,18].
Among them, bacteria predominate with the phyla of the Gram-positive Firmicutes and Gram-negative
Bacteroidetes, mainly involved in the short-chain fatty acids (SCFAs), i.e., acetate, butyrate and
propionate and hydrogen production, respectively. The other phyla are represented by Actinobacteria,
Fusobacteria, Proteobacteria and Verrucomicrobia [19–21]. The precise function of the intestinal flora
remains largely uncharted. However, it processes complexed and indigestible polysaccharides to
SCFAs, providing energy to the host and it also participates in vitamin (i.e., vitamin B and K), bile
acid and amino acid synthesis, drug and toxin metabolism and intestinal barrier preservation. In
particular, the term ‘dysbiosis’ indicates all imbalances between beneficial and pathogen bacteria
or modifications in intestinal flora taxonomic composition and/or function [22]. Perturbations in
intestinal microbiota homeostasis has been already described not only in NAFLD, but also in ALD [10],
T2DM [23], obesity [24,25] and many other diseases [26–29].
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Along the gastrointestinal tract (GIT) from the mouth to colon, the bacterial concentration and
composition is strikingly diverse (increasing from stomach to colon), showing even higher variability
depending on the age, lifestyle, medications and diets. Indeed, a diet enriched in animal fat and sugars
as well as the Western diet may predispose to bacterial overgrowth, immune system activation and
mucosal inflammation both in preclinical [30,31] and clinical studies [32,33].
Several approaches have been developed to study the intestinal flora community diversity,
exploiting quantitative real time polymerase chain reaction (qRT-PCR), sequencing of the 16S
ribosomal RNA (rRNA) gene through next-generation DNA sequencing or partial 16S rRNA
sequencing in the V6–V8 region through pyrosequencing, excepting for Enterobacteriaceae and
Enterococcaceae families [34]. These tools provide information about the abundance and the taxonomy
of microbial species in mucosa-associated colonic tissue biopsies and in fecal samples. All these
techniques are also coupled with the more expensive metagenomics or metatranscriptomics shotgun
approaches [35]. Nonetheless, to study the host-microbiome interactions, intestinal, systemic, uric, and
fecal bacterial-products and metabolites, such as bile acids, SCFAs and endotoxins, can be assessed
by using proteomic and metabolomic methods and may represent diagnostic noninvasive markers,
reflecting the microbiota composition [36].
2.1. Preclinical Models of Microbiota Alterations in NAFLD
Several lines of evidence indicate that intestinal flora composition and function play a paramount
role in the development of obesity and NAFLD [37] and preclinical models are particularly worthwhile
in the understanding of the implications of enteric dysbiosis and bacterial overgrowth in the
pathophysiology of these diseases. Indeed, the unbalanced intestinal flora may exert a detrimental
effect on the host nutrient metabolism thus facilitating overweight and fatty liver onset. In keeping
with this finding, germ-free mice are protected against diet-induced obesity and display less severe
fat accumulation into the liver upon Western diet, supporting the crucial role of intestinal flora in
NAFLD pathogenesis [37,38]. In these mice, the protection against obesity and hepatic steatosis
may be possibly explained by higher circulating levels of Angiopoietin-like 4 (ANGPTL4), a serum
hormone that impaired fat storage in adipocytes, muscles and heart and by the ability of microbiota
to cleave and ferments complex dietary plant polysaccharides [39]. In physiological conditions,
indeed, SCFAs and monosaccharides, resulting from polysaccharides digestion, are absorbed by
the host and delivered to the liver where they are converted to complex lipids. Therefore, the
over-representation of specific classes of bacteria facilitates the catabolism of absorbed nutrients and
through the regulation of the expression of host genes, it promotes energy harvest and storage in
adipocytes favoring the progressive development of obesity and hepatic steatosis [25]. According to
this notion, microbiota transplantation from mice with diet-induced obesity to lean germ-free recipients
promoted greater fat deposition compared to mice transplanted intestinal flora isolated from lean
donors, suggesting that obesity-associated gut microbiota is responsible for the transmission of the
ability to promote fat storage [25]. Furthermore, maternal obesity exacerbated the risk of hepatic
disorders onset in the offspring [40]. Indeed, germ-free mice colonized with stool microbes isolated
from 2-week-old infants born to obese mothers displayed endothelial reticulum (ER) stress, activation of
innate immunity and periportal inflammation, recapitulating the histological pattern of the childhood
NAFLD [40]. The exposure of these mice to a Western diet promoted an excessive weight gain, further
precipitating NAFLD onset [40]. Finally, germ-free mice were also reported to be resistant to high-fat
diet (HFD)-induced IR, showing enhanced hepatic and adipose tissue insulin sensitivity and fecal lipid
excretion [41], revealing that insulin resistance index (HOMA-IR) is transmissible [38].
Multiple preclinical models are currently exploited to study NAFLD development and progression
to advanced stages of liver diseases, resembling human hepatic lesions [42] and recently, these models
have been pointed out to deeply investigate the alterations of gut microbiota composition in the context
of liver injury.
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An unbalance of bacterial species was reported in Leptin deficient mice (Lepob/ob), a genetic model
of obesity, IR and NAFLD, which had enhanced Firmicutes and lower Bacteroides levels, alterations
that have been associated with obesity and subsequent chronic liver diseases [24,25]. Indeed, DNA
sequencing of cecal microbiota of Lepob/ob indicated that the obesity-associated gut microbiome had
an increased capacity for fermenting polysaccharides respect to the lean-associated one, due to the
enhanced prevalence of Firmicutes [24].
As well as Lepob/ob mice, even HFD-fed mice carried a peculiar gut microbiota signature, which
markedly impacted on obesity, IR and lipid metabolism in the liver [38]. Indeed, Le Roy and coworker
demonstrated that gut microbiota play a causative role in the susceptibility to develop NAFLD features
including hyperglycemia, IR and steatosis, in response to the HFD challenge and that the propensity to
develop NAFLD is transmissible by means gut microbiota transplantation [38]. The authors revealed
that alterations in taxonomic composition, such as decreased quantity of Bacteroidetes and increased
levels of Firmicutes, were responsible of NAFLD development, similarly to what occurs in obesity [25].
Specifically, Barnesiella intestinihominis, which was previously related to increased hepatic steatosis and
inflammation [43], was found increased in HFD mice, whereas Bacteroides vulgatus was reduced, as
well as in patients affected by diabetes [44]. Nonetheless, the suppression of intestinal flora via chronic
oral administration of antibiotics attenuated hepatic inflammation and fibrosis in HFD mice, as a result
of the decrease in portal secondary bile acids, supporting the notion that a causal link between gut
microbiota and liver damage exists [45].
Derangement in gut microbiota composition was even described in mice fed methionine-choline
deficient diet (MCD), a dietary model to study NAFLD/NASH in absence of obesity and IR, specifically,
harboring a marked decrease in the abundance of Alistipes and the (Eubacterium) coprostanoligenes group
and a parallel increase in Ruminococcaceae [46].
Gut dysbiosis has been also causally linked to the pathogenesis of cirrhosis and progression to
end-stage liver disease [47]. Depletion of host microflora after gut sterilization could suppress tumor
formation, reducing impressively size and number of nodules in diethylnitrosamine (DEN)-induced
HCC [48]. In line with these findings, Dapito and colleagues reported that mice grown in germ-free
conditions developed smaller and fewer HCC, and treatment with low dose of endotoxins reverted
this situation [49]. These studies demonstrated that gut microbiota and Toll-like receptor 4 (TLR4) are
required for the tumorigenesis promotion, mediating proliferation and prevention of apoptosis [48,49].
2.2. Human Gut Microbiota in NAFLD
An increasing number of studies have demonstrated that bacterial overgrowth may adversely
impact metabolic processes and immune responses, favoring obesity and obesity-related comorbidities,
including NAFLD and IR [50]. However, the precise characterization of dysbiosis in the whole
spectrum of NAFLD lesions has still been unexplored. In 35 consecutive patients with biopsy-proven
NAFLD, Miele et al. demonstrated that NAFLD patients had a significantly increased gut permeability
compared to healthy subjects and the prevalence of small intestinal bacterial overgrowth strictly
correlated with the severity of steatosis, but not with lobular inflammation, ballooning and fibrosis [51].
Even more, patients affected by NASH displayed intestinal bacterial overgrowth, as assessed by the
(14)C-D-xylose-lactulose breath test, increased endotoxins and inflammatory cytokines into the blood
circulation [52]. Thus, the degree of NAFLD is correlated to dysbiosis and to modifications of metabolic
properties of intestinal flora [53].
The main bacterial composition modifications observed in NAFLD patients are represented by
an enrichment in Proteobacteria, Enterobacteriaceae, Lachnospiraceae, Escherichia and Bacteroidetes.
However, there are several discrepancies in the proportion of the latters between the studies and
the results are heterogeneous, mainly due to the presence of obesity and metabolic syndrome as
confounders [54–56].
An unbalance in the ratio between Bacteroidetes and Firmicutes has been reported by Zhu
and colleagues in fecal samples of obese and NASH children [57]. In particular, they assessed the
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composition of gut bacterial communities of 22 biopsy-proven NASH children, of 25 obese subjects
and 16 healthy controls by 16S ribosomal RNA pyrosequencing and they revealed an enhanced
abundance of Bacteroidetes and a decreased number of Firmicutes in fecal samples of obese and
NASH children. Even the levels of Actinobacteria were reduced in NASH individuals, conversely the
quantity of Proteobacteria rose progressively from healthy to obese to NASH patients [57]. The main
finding of this research is the presence of elevated blood levels of alcohol and the highest activities
of alcohol dehydrogenases (ADHs) only in NASH children, due to the increased concentration of
ethanol-producing bacteria from carbohydrate catabolism such as Escherichia coli. In physiological
conditions, indeed, endogenous alcohol is constantly produced by the intestinal microbiota and
rapidly removed from portal blood by hepatic ADHs, catalases and microsomal ethanol-oxidizing
system [58,59]. In NASH-induced dysbiosis, conversely, the over-representation of alcohol-producing
bacteria determined an exaggerated release of ethanol into the blood flow, further corroborating liver
inflammation, reactive oxygen species (ROS) production via the Cytochrome P450 2E1 (CYP2E1) [57,60]
and intestinal hyperpermeability [57].
Fecal dysbiosis and decreased quantity of Firmicutes has been also observed by Wong et al. [55]
in 16 NASH patients compared to 22 controls. The authors showed the presence of lower fecal
abundance of Faecalibacterium and Anaerosporobacter in these subjects but higher abundance of
Parabacteroides and Allisonella [55]. Moreover, Sobhonslidsuk and coworkers highlighted an increase
in the Bacteroidetes/Firmicutes ratio in 16 adult patients affected by NASH independently of age, body
mass index (BMI), diabetes and medications [61]. In particular among the Bacteroidetes phylum, the
Bacteroides and Prevotella genera are the most abundant in NASH subjects [61]. Conversely, Mouzaki
and collaborators revealed a reduction in Bacteroidetes and higher levels of fecal Clostridium coccoides
in 22 NASH subjects compared to 17 healthy subjects and 11 simple steatosis, thus facilitating the
growth of other bacterial species and the override energy intake from dietary fat [24,25,62]. The
variety in the proportion of Bacteroidetes and Firmicutes observed by Zhu and colleagues [57] and
Mouzaki et al. [54] may reflect the diversity in age, BMI, environmental and dietary factors of the two
study cohorts. Therefore, to rule out the impact of obesity on gut microbiota composition, Wang B. and
colleagues sought to identify the variability in fecal microbiota composition between non-obese adult
individuals with and without NAFLD (43 NAFLD vs. 83 healthy controls) [63]. They demonstrated that
adult non-obese NAFLD patients harbored 20% more phylum Bacteroidetes and 24% less Firmicutes,
showing a significant correlation of metabolic markers with the disturbed microbiota in NAFLD [63].
Hence, the prevalence of Firmicutes is considered a fingerprint of obesity-associated NAFLD, whereas
the Bacteroides override is related to ‘lean’ NAFLD.
Overwhelming evidence provided by Loomba et al. suggested the presence of gut
microbiota-derived signature, which predicts the presence of advanced fibrosis in NAFLD patients [64].
Through a whole-genome shotgun sequencing approach on stool samples, the authors analyzed the
bacteria taxonomic composition of 86 biopsy-proven NAFLD of whom 72 had mild fibrosis and 14
had advanced fibrosis (stages 3/4). They identified 37 different bacterial species, which enabled us to
distinguish mild and advanced fibrosis in NAFLD patients and they showed that advanced fibrosis
is characterized by an exasperation of Proteobacteria and Escherichia coli along with a decrease in
Firmicutes [64]. The same research group, in a very recent paper, identified the specific intestinal
microflora profile of NAFLD cirrhotic patients, determining a panel of 27 fecal bacteria that may
discriminate NAFLD cirrhosis using a random forest classifier model [65]. Besides, Boursier et al.
determined the presence of rising quantity of Ruminococcus in NASH patients affected by advanced
fibrosis, while Prevotella abundance was decreased [53] and higher counts of Escherichia coli and
Staphylococcus have been found in stool samples of subjects with mild encephalopathy and cirrhosis [66].
Quantitative metagenomic analyses identified 75,245 genes that differ cirrhotic patients from healthy
individuals [67], showing fewer Bacteroidetes but higher levels of Proteobacteria and Fusobacteria [67].
Schierwagen and colleagues focused on the assessment of the circulating microbiome in the portal vein
of seven patients with decompensated cirrhosis, during the implantation of a transjugular intrahepatic
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portosystemic shunt and they demonstrated that 65 genera belonging to four phyla, predominantly
Proteobacteria, were strictly correlated with cytokines secretion [68].
Finally, addressing to fecal microbiota diversity in HCC patients, Ren Z. and coworkers revealed
an enrichment in the phylum Actinobacteria and in 13 genera, including Gemmiger and Parabacteroides
in fecal samples of 75 HCC patients compared to 40 cirrhotic ones. In particular, butyrate-producing
genera were decreased, while lipopolysaccharides (LPS)-producing genera were increased in early
stage of HCC [69].
Collectively, these findings suggest that manipulation of intestinal microflora may be a strategy to
prevent or treat NAFLD and metabolic syndrome features.
3. Gut–Liver Axis: New Awareness in NAFLD Pathogenesis and Progression
The gut–liver axis has many implications in NAFLD onset as the major contributor of the intestinal
dysbiosis, possibly due to the tight anatomo-functional crosstalk of the two organs. The liver is
perpetually exposed to gut microbial end-products and nutrients via the portal vein (70% of blood
supply) and, in turn, participates to bacterial composition through bile acids cycling released into the
duodenum lumen with the enterohepatic circulation [10]. Alongside, the gut microbiome composition
is crucial to modulate innate and adaptive immune response both locally and systemically, facilitating
host defense against pathogens.
The bowel wall plays an essential role as a selective barrier that regulates the bidirectional flux
between the gut and the liver, since it is constituted by tight and adherent junctions (occludins,
claudins and Zonula Occludens 1 (ZO-1)) and desmosomes, which hold together the epithelial cells.
Furthermore, it exerts many immunological functions as it is constituted by multiple layers and
specialized cells, such as Goblet, Paneth and plasma cells secreting mucus, antimicrobial peptides (i.e.,
defensins, lysozyme and c-lectin Reg3b/g) and Immunoglobulin A (IgA), respectively. Together they
protect the host from invasive pathogens and avoid bacterial overgrowth and systemic translocation [10].
The excessive erosion of the protective mucus layer as well as the reduction of antimicrobial mediators
has been associated with translocation of pathogenic microorganisms in both preclinical and human
studies [70,71].
Disturbance of the intestinal barrier integrity, a phenomenon known as leaky gut, along with
shifting in metabolic function of gut microbiota, are frequently present in patients with NAFLD-related
dysbiosis [51,72] and correlate with NAFLD severity. Indeed, a relative abundance in Bacteroides and
Ruminococcus have been independently associated with NASH and fibrosis [73]. As a consequence
of enhanced gut permeability, much more bacteria and potentially harmful byproducts translocate
into circulation and reach the liver thus contributing to the increase of circulating gut-derived toxins
(endotoxemia) and the establishment of chronic low-grade inflammatory state that features metabolic
disorders such as obesity and NAFLD [74,75]. Several endogenous molecules as ethanol, ammonia and
acetaldehyde, whose circulating increased levels result from dysbiotic microbiota (i.e., Escherichia coli
abundance), are able to stimulate hepatic Kupffer cells to produce pro-inflammatory cytokines with
similar mechanisms occurring in ALD [10,57]. Likewise, LPS and peptidoglycans derived from
Gram-negative and Gram-positive bacteria walls are the most representative pathogen-associated
molecular patterns (PAMPs), which activate Toll-like receptors (TLRs) signaling. In particular,
LPS-induced TLR-4 cascade in hepatocytes, Kupffer cells and hepatic stellate cells (HSCs) leading to
elevated systemic levels of tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL6) via nuclear
receptor kappa B (NF-kB) thus promoting IR, inflammation and fibrosis [9,76]. Otherwise, circulating
free fatty acids (FFAs), whose levels are commonly higher in NAFLD, may independently stimulate
TLR4 and TLR2 inflammatory pathways [77,78]. Furthermore, peptidoglycans and damage-associated
molecular patterns (DAMPs) contribute to liver damage through the crosstalk between TLRs (e.g.,
TLR2 and TLR5) and inflammasome via intracellular nucleotide-binding and oligomerization domain
(NOD)-like receptors (NLRs), which increase IL1 and IL8 production in hepatocytes, Kupffer cells and
HSCs [60].
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Moreover, alteration of gut microflora communities contributes to liver pathology and disruption
of intestinal barrier integrity. For instance, dysbiosis may affect lipid metabolism and trafficking in
both liver and adipose tissue by upregulating lipogenic enzymes or lipoprotein lipase (LPL) thus
participating to obesity and steatosis development. Interestingly, several intestinal bacteria species
dampen the production of the Fating-Induced Adipocyte Factor (FIAF), whose downregulation
is associated with increased adiposity and hepatic de novo lipogenesis [79]. Enrichment in
Cytophaga–Flavobacter–Bacteroides phyla influences the development of fatty liver and hepatic
inflammation favoring IL7 release from T-helper cells (Th17) [80]. Dietary choline is further metabolized
by enteric bacteria in trimethylamine and then it is converted in the hepatotoxic trimethylamine N-oxide
(TMAO) end-product. Indeed, choline shortage or increased TMAO production have been associated
with higher levels of Gram-negative Gammaproteobacteria and Erysipelotrichi and with steatosis since
its levels are crucial to favor very-low density lipoprotein (VLDL) assembly and secretion.
Microbial SCFAs may affect the intestinal barrier integrity and mucosal immune tolerance raising
levels of intestinal SCFAs-producing species strengthen barrier integrity supporting tight junctions and
mucins production and operating as energy source for intestinal mucosal cells [81,82]. For example,
the reduction of produce butyric acid, produced by Faecalibacterium prausnitzii, weakens the few
connections between intestinal epithelial cells, by decreasing the expression of the tight junction
proteins and mucins. The restoration of the physiological abundance of microorganisms-producing
butyrate, in turn, may ameliorate the gut high permeability and systemic inflammation [83].
The molecular features of the gut–liver axis in NAFLD/NASH are schematically represented in
Figure 1A.
3.1. Bile Acids Pool: A Fine-Tuning Regulator of Intestinal Barrier Integrity
Emerging evidence has suggested that alterations in bile acids metabolism are associated with
chronic liver diseases and comorbidities, i.e., development of cholestasis. The liver synthetizes primary
bile acids, which first accumulate in the gallbladder and then are released in the duodenum lumen
where they are converted in secondary bile acids by the gut microbiota and favor lipid solubilization,
emulsification and absorption. In addition, bile acids act as signaling molecules (i.e., deoxycholic acid
(DCA) and di-hydroxy chenodeoxycholic acid (CDCA)) as they activate the intestinal Farnesoid X
Receptor (FXR), leading to the release of Fibroblast Growth Factor 19 (FGF19), which can modulate gut
barrier integrity, and β-Klotho in the bloodstream [10]. Both FGF19 and β-Klotho can downregulate
bile acids synthesis in the liver by inhibiting cholesterol 7-α hydroxylase 1 (Cyp7A1) [84]. The
enhanced production of bile acids pool can also stimulate Takeda G-protein-coupled receptor 5
(TGR5) to activate the proinflammatory cascade on Kupffer cells surface [85]. Indeed, patients with
NASH showed elevated levels of cytotoxic bile acids in the liver, serum, stool and urine, which
may worsen liver damage to cirrhosis [86–88]. To date, many FXR agonists with hepatoprotective
properties (i.e., obeticholic acids) have been proposed as they are able to reduce hepatic steatosis and
necroinflammation [88,89]. However, the prolonged exposure to bile acids analogues is associated with
severe side effects. Therefore, alternative approaches, such asω-3 long-chain polyunsaturated fatty
acids administration and/or combined to gut microbiota modulation, which may have the advantage
to adjust bile acid pool, is still under investigations for the treatment of NAFLD [90,91].
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Figure 1. Role of the gut–liver axis in progressive nonalcoholic fatty liver disease (NAFLD) and
probiotic-related beneficial mechanisms. We summarized the main abnormalities involved in dysbiotic
NAFLD and the impact of probiotic treatment on the gut–liver axis. (A) Obesity, diet and physical
inactivity favor hepatic steatosis, disruption of the intestinal barrier and alter microflora taxonomic
composition (dysbiosis). This condition may promote gut hypermeability through loosening tight
junction proteins (ZO-1 and claudins), thinning mucus layer (Muc2), reducing antimicrobial peptides
and IgA secretion. The leaky gut stimulates a pro-inflammatory local milieu, recruiting macrophages,
dendritic cells (DCs), T CD4+ and T CD8+ as well as promoting phenotype switch of B cells into plasma
cells. This pathologic microenvironment facilitates the systemic translocation of pathogenic bacteria and
gut-derived pathogen-associated molecular patterns (PAMPs)/damage-associated molecular patterns
(DAMPs; such as lipopolysaccharides (LPS) and peptidoglycans). Upon arrival to the liver via portal
vein, PAMPs/DAMPs and high levels of free fatty acids (FFAs) activate inflammatory response in
hepatocytes, Kupffer cells and hepatic stellate cells (HSCs) through Toll-like receptors (TLRs) cascade,
which enhances the release of cytokines and chemokines (such as TNFα, IL1, IL6, IL8 and IFN-γ) and
worsens liver damage. (B) Probiotics may restore intestinal barrier integrity, positively acting on ZO-1
expression, mucus thickness and commensal bacteria proportion (eubiosis). Moreover, they participate
to the shutdown of bowel inflammation, enrolling T regulatory cells, DCs and macrophages to secrete
anti-inflammatory cytokines (TGF-β and IL10). In the liver, the reduction of endotoxemia halts hepatic
damage, as shown by lower aminotransferases (ALT and AST) and contributes to the recovery of
the hepatic functions, affecting the lipid composition of fatty-laden hepatocytes, favoring endotoxins
clearance, as well as negatively impacting on inflammatory and fibrogenic processes (i.e., lower iNOS,
MMP and NF-kB).
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3.2. Features of the Gut–Liver Axis in NAFLD and NASH
The implication of the gut–liver axis in the susceptibility of NAFLD has been widely investigated
in both preclinical and human studies, although it remains a matter of debate. Nevertheless, new
insights in the pathogenesis and progression of NAFLD have been attributed to the permeable gut
barrier as it constitutes a favorable microenvironment for bacteria overgrowth, promotes endotoxemia
and contributes to chronic liver damage in response to endogenous or exogenous cofactors, such as
dietary pattern and lifestyle. Indeed, fatty liver is highly prevalent in obese patients and the 20%–30%
of pathologically obese individuals show histological signs of necroinflammation and fibrosis [92,93],
possibly even for diet-induced derangement of barrier integrity.
It has been demonstrated that the interaction between HFD and enteric bacteria promote intestinal
inflammation through TNF-α production and NF-kB activation, a mechanism that precedes IR
development in mice [94]. In NAFLD rats feeding high sucrose and high fat (HSHF) diet, Zhou et al.
showed that animals exhibited damaged villous of the intestinal epithelium and low-grade inflammatory
status due to increasing gut-derived endotoxins and inflammatory cytokines that translocate into the
circulation [95]. Interestingly, Brun et al. revealed that leptin-deficient (Lepob/ob) and hyperleptinemic
(Lepdb/db) obese mice displayed a dysmorphic mucosal barrier as demonstrated by a dramatic ZO-1 and
tight junctions redistribution, and a remarkable release of IL1, IL6, TNF-α and Interferon (IFN-γ) in the
portal vein [96]. Notably, sodium butyrate supplementation to HFD fed mice improved gut mucosa
restoring intestinal ZO-1 levels and favoring abundances of the beneficial bacteria Christensenellaceae,
Blautia and Lactobacillus [97]. Butyrate further impacts on liver damage, strongly reducing hepatic fat
accumulation as well as markers of inflammation and fibrosis [97]. Nonetheless, HSCs isolated from
Lepob/ob and Lepdb/db livers chronically exposed to LPS showed a pro-inflammatory and pro-fibrotic
phenotype compared to HSCs isolated from lean mice, supporting that increased intestinal permeability
may participate to the development and progression of obesity-related NASH [96].
Chronic fructose intake has been associated with loss of tight junction proteins and lower
SCFA-producing agents, which foster PAMPs translocation, increase numbers of macrophages in the
liver and activate TLR1-9 and myeloid differentiation factor 88 (Myd88)-dependent proinflammatory
pathways in mice [98]. Similarly, acute and chronic high fructose consumption exacerbated endotoxemia
in pediatric NAFLD and even correlates with markers of IR and liver inflammation [99]. Noteworthy,
the G protein-coupled chemokine receptor CX3CR1 protects mice from steatohepatitis induced with
HFD or MCD diet as it maintains intestinal homeostasis and barrier integrity [100].
Finally, in a model of early NASH induced with high glucose/fructose diet (HFGFD), the authors
observed that rats developed portal hypertension, a severe complication of liver cirrhosis. Hence, they
investigated whether enteric dysbiosis could modulate endothelial and hepatic functions. Notably,
HFGFD-fed mice were enriched in Firmicutes rather than Bacteroides strains and selectively activated
intestinal FXR thus suggesting that changes in intestinal microbiota communities impair bile acid
metabolism, which, in turn, may be a driver of NASH-related complications [101].
3.3. Features of the Gut–Liver Axis in Cirrhosis and HCC
The aforementioned mechanisms further influence liver damage progression, possibly leading
to advanced fibrosis and cirrhosis, the end-stage of chronic liver disease and the leading cause of
liver failure and HCC. Activated HSCs show high LPS-induced TLR4 responsiveness thus repeatedly
enhancing pro-fibrotic processes that compromise immune defense and toxins clearance from hepatic
tissue supporting cirrhosis development [102]. Moreover, LPS/TLR4 signaling plays a critical role to
induce hepatocarcinogenesis by promoting a senescence-associated secretory phenotype (SASP) in
HSCs and stimulating chemoattractant cytokines production from HSCs and monocytes. Bacterial
translocation even participates to hemodynamic complications linked to cirrhosis, such as hepatic
encephalopathy, variceal bleeding and portal hypertension. Recently, Sorribas et al. showed that
cirrhotic mice reduced mucus thickness and lost Goblet cells as well as mucins expression, allowing
bacterial overgrowth and the pathological translocation of Escherichia coli [103]. Assimakopoulos et al.
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firstly demonstrated that leaky gut exerts a pivotal role in human cirrhosis, highlighting the
importance of occludin and claudin 1 downregulation in cirrhotic patients and even more in those
with decompensated cirrhosis [104]. In addition, higher levels of IL6, nitric oxide (NO) and decreased
transepithelial resistance have been associated with the presence of activated intestinal macrophages
in cirrhotic patients [105].
Obesity-induced changes in gut microbiota composition may raise the amount of DCA that
has been associated with SASP phenotype in HSCs, which enhance pro-inflammatory cytokines and
tumor-promoting factors, as well as DNA damage and ROS production in the liver [106,107]. In an
experimental model of HCC induced with DEN, alterations in gut permeability seems to be the primary
hit leading to amplified tumorigenic response of the liver to LPS. Indeed, antibiotics regimen or TLR4
ablation mitigated tumor growth and multiplicity in mice [48]. Dapito et al. exposed C3H/HeJ and
C3H/HeOuJ mice to a mixture of DEN and hepatotoxin carbon tetrachloride (CCL4), a model that
resembles human microenvironment for HCC raise, and demonstrated that intestinal microbiota and
TLRs promote liver cancer as a long-term consequence of chronic liver injury [49]. In a most recent
study, Ponziani and collaborators investigated the gut microbiome profile and intestinal features of 21
NAFLD patients with both cirrhosis and HCC compared to 20 cirrhotic individuals without HCC and
healthy controls. Although they found a similar degree of intestinal barrier dysfunction between HCC
and cirrhotic subjects, systemic levels of IL8, IL13, Chemokine C-C motif Ligand 3 (CCL3), CCL4 and
CCL5 significantly correlated with circulating activated monocytes in presence of HCC [108].
4. Probiotics: Cunning Double-Crossers Against Their Household
Current interventions for the management of NAFLD focused on dietary and lifestyle modifications,
although the discouraging results due to the poor compliance of patients. In addition, hypolipidemic
drugs, anti-TNFα, antioxidants and diabetes medications have been proposed for NAFLD/NASH, even
though no pharmacological therapies or surgical procedures have been approved for the treatment of
NAFLD. In the last decade, intensive efforts have been directed to develop new strategies targeting the
gut–liver axis as it appears as an attractive converging point for the prevention of NAFLD onset and/or
progression. Several approaches to modulate dysbiosis include 1) untargeted methods (diet, probiotics,
prebiotics, antibiotics and fecal microbiota transplant (FMT)) or 2) microbiota-targeted therapy (MTT)
which selectively target microbial and host metabolites [109].
The mechanisms by which unbalancing in gut microbiota participate to liver pathology remains
still uncertain; however promising results on modulation of intestinal flora have been reported in
several preclinical and human studies. Increasing efforts have been addressed to exploit the ability of
probiotics to reverse gut dysbiosis and only recently they have been proposed as treatment of NAFLD.
Probiotics are defined as a “live microorganism that—when administered in adequate
amounts—confer a health benefit on the host” by the World Health Organization/Food and Agriculture
Organization (WHO/FAO). The criteria for the selection of probiotic strains are represented by the safety
(i.e., absence of genes responsible for antibiotic resistance), functionality (i.e., resistance of lower pH in
the stomach) and technological usability (i.e., high survival rate in finished products) [110]. Among
them, commercialized Streptococcus/Lactobacillus/Bifidobacteria promote anti-inflammatory environment
and help intestinal epithelium growth and survival as well as they may counteract the pathogenic
bacteria by modulating immune system and host defense [111].
The present chapter would deeply highlight the most recent findings on health benefits gained
with probiotic administration in the experimental models of NAFLD and in the clinical practice.
The probiotics benefits on the gut–liver axis in NAFLD/NASH are summarized in Figure 1B.
4.1. Probiotics in the Preclinical Studies of NAFLD
Numerous studies demonstrated that probiotics administration might attenuate NAFLD features
in animal models [112–116]. The administration of VSL#3, a mixture of three genera of bacteria (a
multistrain formulation composed by Streptococcus, Thermophilus and several species of Bifidobacterium
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and Lactobacillus) for 4 weeks to Lepob/ob mice improved insulin sensitivity, total fatty acid content,
serum alanine aminotransferase (ALT) levels and the histological spectrum of liver damage [112].
These improvements were mainly due to the reduction of Jun N-terminal kinase (JNK) and NF-kB
activation and to the decreased expression of Uncoupling protein (UCP)-2 in Lepob/ob mice exposed to
VSL#3, sustaining the hypothesis that intestinal bacteria may regulate the activation of host signaling
pathways interfering with hepatic insulin response and lipid metabolism [112].
Nonetheless, VSL#3 supplementation in HFD-challenged young rats, dampened the production
of TNF-α, inducible nitric oxide synthase (iNOS), metalloproteinases (MMP) and Cyclooxygenase 2
(COX-2), as well as it improved lipid peroxidation markers, limiting oxidative and inflammatory damage
in the liver [115]. These findings are even supported by Ma X. et al.’s study, in which VSL#3 probiotics
exposure ameliorates IR, steatosis and pro-inflammatory cytokines secretion, hampering NF-kB activity
in HFD-fed mice [113]. Furthermore, oral Bifidobacterium longum supplementation in HFD-fed rodents
for 12 weeks reduced hepatic fat accumulation more than the administration of Lactobacillus acidophilus,
irrespectively of intestinal permeability restoration [117]. In addition, Lactobacillus johnsonii BS15
protected HFD mice from hepatic steatosis and hepatocyte apoptosis, exhibiting a positive effect
on lipid peroxidation, sustaining the antioxidant defense system and improving mitochondria
abnormalities [118]. The restoration of Bifidobacteria or Akkermansia muciniphila along with oligofructose
implementation reduced endotoxemia, hepatic fat deposits and metabolic syndrome hallmarks in HFD
mice [119]. Moreover, diabetic rats administered with Akkermansia muciniphila improve liver function,
reduce gluco/lipotoxicity, alleviate oxidative stress, suppress inflammation and normalize intestine
microbiota thereby ameliorating type 2 diabetes mellitus [120]. Similarly, nano-selenium-enriched
Bifidobacterium longum delay the onset of streptozotocin-induced diabetes [121].
In a model of inherited dyslipidemia (ApoE-/-mice), the modulation of gut microbiota through
VSL#3 mixture rescued hepatic and adipose tissue IR and counteracted atherosclerosis and NAFLD
onset [122]. Specifically, VSL#3 reversed IR, prevented development of histologic features of mesenteric
adipose tissue inflammation, NASH and reduced the extent of aortic plaques, through the modulation
of Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ), FXR and vitamin D receptor [122].
Velayudham and collaborators demonstrated that VSL#3 may even influence fibrosis development
in MCD fed mice, favoring the reduction of collagens, MMPs and α-smooth muscle actin (α-SMA),
not accompanied by the attenuation of hepatic steatosis and inflammation [116]. In agreement
with Velayudham’s study, even Nardone and collaborators revealed the protective effect of
Lactobacillus paracasei F19 (LP-F19), in an experimental model of ischemia-riperfusion in rats fed
MCD [114]. Likewise, heat killed Lactobacillus reuteri GMLN-263 rescued hepatic and heart fibrosis,
resetting the expression of pro-fibrotic markers, such as the transforming growth factor β (TGF-β)
in HFD hamsters [123]. Alongside LP-F19 and GMLN-263, many other strains of Lactobacillus, i.e.,
Lactobacillus reuteri GMLN-13, have been demonstrated to attenuate the harmful impact of gut microbiota
derangement in the contest of NAFLD and NAFLD-related comorbidities, such as hypertension, obesity,
glucose intolerance, hyperglycemia, hyperinsulinemia, dyslipidemia, adipose tissue inflammation and
oxidative stress [124–127].
In rodents, daily oral VSL#3 administration was next reported to be related to the restoration
of enterocyte architecture and of intestinal barrier integrity by inducing mucus secretion, Muc2
colonic expression and ileal occludin levels, and avoiding viable microorganisms and bacterial
products translocation into the bloodstream [128]. The expression of tight junction proteins (i.e.,
occludins, claudins and ZO-1) was forced by the supplementation with Lactobacillus rhamnosus,
Lactobacillus paracasei and Bifidobacterium adolescentis [109]. Intriguingly, Clostridium butyricum strain
MIYAIRI 588, a butyrate-producing probiotic, prevented the entire pathological spectrum of NAFLD,
from steatosis to HCC in a rodent model of choline-deficient/L-amino acid-defined (CDAA)-diet,
re-establishing the intestinal barrier integrity [129]. Besides, MIYAIRI 588 positively affects the
development of IR, excessive triglyceride storage and attenuates serum endotoxin concentration,
hepatic inflammation and oxidative stress [129]. Finally, Lactobacillus johnsonii La1 in combination
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with antioxidants prevented bacterial translocation and endotoxemia in a rat model of CCl4-induced
cirrhosis, enlightening the idea to use probiotics and antioxidants as alternative strategy to antibiotics
in the prevention of bacterial infections in cirrhotic patients [130].
Complexively, probiotics supplementation may positively intervene on the liver injuries induction
in rodent models of NAFLD although most of the studies are addressed to prevent rather than treat
diet-induced liver disease.
4.2. Use of Probiotics in Human NAFLD, Cirrhosis and HCC
Over the year, the experimental models of NAFLD have collected promising findings in the field
of microbiome therapeutics thus providing greater awareness for the clinical evaluation of probiotics
to overthrow NAFLD development and progression.
Vajro et al. conducted a double-blind study on 20 obese children with ultra-sonographic proved
steatosis that were randomized for Lactobacillus rhamnosus GG or placebo for 8 weeks. Despite probiotic
administration had no effect on adiposity and fatty liver, it has been suggested as treatment for
hypertransaminasemia in obese children noncompliant to lifestyle interventions [131]. Similar findings
of reduced ALT and aspartate aminotransferases (AST) have been observed in 30 adults affected by
NASH exposed to Lactobacillus acidophilus compared to those receiving placebo [132].
The effects of probiotics as a combination of multistrains compound have reached better outcomes
in randomized trials. Famouri et al. carried out a triple-blind trial on 64 obese children with
sonographic NAFLD. Adolescents receiving a probiotic capsule of Lactobacillus acidophilus ATCC B3208,
Bifidobacterium lactis DSMZ 32,269, Bifidobacterium bifidum ATCC SD6576 and Lactobacillus rhamnosus
DSMZ 21,690 for 12 weeks showed significant reduction in ALT, lipid profile and intrahepatic fat
content evaluated with ultrasound compared to placebo group. In a randomized placebo-controlled
trials (RCT), Kobyliak et al. assessed the efficacy of “Symbiter”, containing 14 alive probiotic strains of
Lactobacillus + Lactococcus, Bifidobacterium, Propionibacterium and Acetobacter, in NAFLD patients. The
multiprobiotic cocktail ameliorated hepatic steatosis, aminotransferase activity, TNF-α and IL6 levels
in patients with NAFLD [133]. Similarly, patients with histology-proven NASH randomly receiving
Lepicol probiotic formula for 6 months attenuated intrahepatic triglycerides and reduced serum AST
levels [134]. In a meta-analysis conducted by Ma et al., including 134 NAFLD/NASH from four
randomized trials, the authors underlined that probiotic therapy with Lactobacillus, Bifidobacterium and
Streptococcus beneficially impacts on hepatic fat content, total cholesterol, levels of aminotransferases
and HOMA-IR [135]. Most recently, Gao and collaborators evaluated the efficacy of probiotic treatment
in both pediatric and adult NAFLD including nine RCT with a total of 535 NAFLD cases [136].
They showed that probiotics improve the clinical outcomes of NAFLD patients, influencing insulin
sensitivity and reducing TNF-α. However, probiotics ameliorated dyslipidemia only in Italian and
Spanish population, suggesting that the effects of these molecules on high-density lipoprotein (HDL),
low-density lipoprotein (LDL) and triglycerides might depend on ethnical background [136].
It has been demonstrated that VSL#3, the most studied multistrains probiotic, protects intestinal
barrier integrity, dampens endotoxemia and oxidative/nitrosative stress thus favoring improvement in
liver pathology in patients with different chronic liver diseases, among which 20 with ALD and 22 with
NAFLD [10,137]. In a double-blind RCT (NCT01650025), in which were enrolled 48 pediatric NAFLD,
4 months VSL#3 supplementation improves severity of NAFLD as a consequence of VSL#3-induced
eubiosis [138]. Administration of Bifidobacterium longum along with the prebiotic fructo-oligosaccharides
(FOS) strongly improved circulating metabolic and inflammatory markers and fibrosis scores in patients
with biopsy-proven NASH [139]. Intriguingly, the presence of Bifidobacterium longum in the VSL#3
compound modulates gut microbiota to produce conjugated linoleic acid (CLA), which, in turn, affect
fatty acid composition in the liver further corroborating that the interplay between the gut and the
liver in NAFLD assumes a relevant role for the development of therapeutic interventions.
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In a phase I study, consumption of Lactobacillus GG for 8 weeks induced changes in gut microbiome
of cirrhotic patients with minimal hepatic encephalopathy (n = 30), which reduced the abundance
of Enterobacteriaceae, endotoxemia and TNF-α and facilitated the intestinal growth of Clostridiales
Incertae Sedis XIV and Lachnospiraceae [140]. Recently, Romàn et al. evaluated the effect of a mixture
of eight strains for 12 weeks in 36 patients with cirrhosis and found that the multistrain probiotic
improved cognitive function, lower the incidence of falls at the follow-up and decreased inflammatory
responses [141]. Conversely, in a randomized double-blind RCT including 44 cirrhotic outpatients, the
long-term probiotic supplementation consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis
W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius
W24, Lactococcus lactis W19 and Lactococcus lactis W58, significantly influenced neutrophil resting burst,
but not circulating endotoxins, gut permeability or inflammatory markers [142]. Although many of the
current studies on effectiveness of probiotics are disappointing, this preliminary data has suggested
that they are a well-tolerated and safe in cirrhotic subjects.
Few studies regarding the use of probiotics as HCC therapy have been reported in humans.
Remarkably, it has been observed that preoperatively and postoperatively probiotic supplementation
in patients with HCC who underwent hepatic resection favored liver function recovery and showed
reduced frequency of intraoperative and postoperative complications [143].
5. Focus on Clinical Trials Regarding NAFLD and Probiotics
The effect of probiotics on NAFLD development and on metabolic syndrome is currently
investigated in larger and long-term clinical trials. Indeed, the impact of the dietary supplementation
for 6 months with Lactobacillus acidophilus ATCC SD5221 and Bifidobacterium lactis HN019 on hepatic
changes in NASH patients is under definition in the single-center double blind, placebo controlled,
parallel group study NCT02764047 [134,137,144,145]. The main outcomes of this study are the
noninvasive evaluation of fibrosis, AST, ALT, the restoration of gut microbiota and the amelioration
of the lipid profile via the measurement of circulating total cholesterol, HDL, LDL and triglycerides.
The effectiveness of the probiotics in improving the liver functions is also the topic of the randomized,
double-blind, placebo-controlled trial NCT04074889 of 6 months duration. This study assessed hepatic
inflammation, fibrosis and intestinal permeability in NAFLD patients after the administration of a
mixture of Lactobacillus and Bifidobacterium containing probiotics (Lactobacillus acidophilus, Lactobacillus
casei subsp, Lactobacillus lactis, Bifidobacterium bifidum, Bifidobacterium infantis and Bifidobacterium longum).
The randomized interventional study NCT01922830 tested the dietary supplementation to NAFLD
obese subjects who underwent bariatric surgery with a mixture of different bacterial species (in the
formulation of Bio-25 (Supherb) consisting of 11 different species of patented probiotic bacteria).
Likewise, even in NCT03585413 it has been evaluated the effect of gut microbiota manipulation
and the mini-gastric bypass surgery in the contest of obesity. Moreover, phase II of NCT03511365
clinical trial investigated the alteration of serum inflammatory markers and fecal microbiota following
the administration of VSL#3 in patients with NAFLD. Finally, NCT03511365 and NCT02972567
are currently recruiting patients with NASH with the aim to ameliorate hepatic inflammation and
fibrosis and to improve the prognosis of these patients and their cardiovascular risk, after intestinal
microbiota restoration.
The efficacy of probiotics in metabolic disease remains a matter of debate and probably it
necessitates further investigations to evaluate their safety, doses and short/ long-term exposure and the
benefits to be administered alone or in combination with current therapy for NAFLD.
A schematic description of the main ongoing clinical trials is represented in Table 1.
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Table 1. Clinical trials underway addressing the therapeutic modulation of gut microbiota in NAFLD patients.
Clinical Trial
Start-End Date Status Study Type Interventions Conditions Objectives Locations
NCT02764047
04/15–12/17
[134,137,144,145]
Recruiting
(n = 58) *
Interventional
Randomized
109 Lactobacillus acidophilus
ATCC SD5221 and 109
Bifidobacterium lactis HN019
vs. placebo
NASH
Evaluate the effect of supplementation
of probiotics on liver changes
(histological and enzymatic), lipid
profile and gut microbiota
Federal University of
Health Science of Porto
Alegre
NCT03528707
04/15–05/18
Completed
(n = 48)
Interventional
Randomized
Dietary Supplement
Symbiter Omega for 8
weeks vs. placebo
T2DM with NAFLD
Assess the impact of co-administered
multi-strains probiotic and omega-3 on
steatosis, lipid profile and inflammation
Bogomolets National
Medical University
NCT01922830
08/13–01/19
Active, not recruiting
(n = 100) *
Interventional
Randomized
Dietary Supplement:
Bio-25 (Supherb) vs. mimic
Bio-25 pill
NAFLD patients
undergoing sleeve
gastrectomy surgery
Investigate the benefits of 6 months
probiotic supplement on clinical and
metabolic parameters in patients with
NAFLD Bariatric Surgery
Tel-Aviv Sourasky
Medical Center
NCT04074889
08/19–12/20
Recruiting
(n = 48) *
Interventional
Randomized
Microbial cell preparation
(Hexbio) for 6 months vs.
placebo sachet with no
microbial cell preparation
NAFLD
Evaluate intestinal barrier function, local
gut inflammation and the clinical
outcomes in NAFLD patients.
Universiti Kebangsaan
Malaysia Medical Centre
NCT03511365
05/18–08/19
Enrolling by
invitation
(n = 20) *
Interventional
Single Group
Assignment (phase II)
VSL#3 vs. placebo NAFLD
Examine the alterations in serum
inflammatory markers and fecal
microbiota after VSL#3 supplementation
Northwell Health,
Manhasset, New York,
United States
NCT03467282
03/18–08/19
Recruiting
(n = 46) *
Interventional
Randomized
1 g probiotic mix (twice
day) vs. 1 g
polydextrose/maltodextrin
NASH
Analyze the microbiota modulation,
degree of hepatic steatosis, inflammation
and fibrosis, and body composition
Hospital de Clinicas de
Porto Alegre
Porto Alegre, RS, Brazil
NCT03585413
08/18–08/21
Recruiting
(n = 60) *
Interventional
Randomized
(phase III)
micronutrient-probiotic-
supplement vs. placebo
Obese patients
undergoing to
mini-gastric bypass
surgery
Investigate the effect of probiotic on fatty
liver, IR, NAFLD/NASH progression
and cardiometabolic diseases.
St. Franziskus-Hospital
Cologne, Germany
NCT02972567
10/16–06/17
Recruiting
(n = 60) *
Metabolic
Syndrome X
Assess changes in intestinal microbiota,
lipid profile, markers of inflammation,
hypertension, cardiovascular risk and
hepatic steatosis.
Complejo Hospitalario
Universitario de Jaen,
Jaen, Spain
Interventional
Randomized
(phase II)
1 capsule/day of Lactobacillus spp
for 12 weeks vs. maltodextrin
* Estimated number of participants.
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6. Conclusions
Through different routes, gut microbiota composition and function are strongly entangled in the
pathogenesis and the progression of liver injury in patients with metabolic syndrome and NAFLD, the
major health concerns in children and adult population. In particular, intestinal bacterial overgrowth,
dysbiosis and intestinal barrier derangement along with several other issues concur to increase
individual susceptibility to NAFLD. Further studies are essential to completely draft the true causality
between changes observed in the context of NAFLD and comorbidities as well as to pinpoint the
mechanisms through which microbiota alterations affect liver pathology. To date, clinical guidelines
indicate dietary interventions and lifestyle modifications as a gold standard for the treatment of
NAFLD and its comorbidities, although the discouraging results due to the poor compliance of
patients. Therefore, there is an urgent need to identify alternative therapeutic strategies to tailor
NAFLD management.
Several studies and clinical trials have encouraged the use of probiotic supplementation as
promising and safe therapeutic approach, highlighting the uncharted avenue of the intestinal microflora
restoration as a cornerstone in the standard of clinical care of NAFLD patients. Trustworthily,
addressing gut microbiota as a new driving direction for the future medicine will brighten the avenue
of personalized interventions. Nevertheless, microbiota composition investigation could become an
appealing candidate even for diagnosis, attempting to profile liver disease stage. In addition, probiotics
could be administered alone or in a combination with NAFLD current therapies although their synergic
effects remain largely unexplored.
To date, the efficacy of probiotics in NAFLD management is unknown and limited to hypotheses.
However, extensive studies are essential to completely pinpoint the mechanisms through which
microbiota alterations affect liver pathology in NAFLD patients and to identify the most effective
probiotic strains, their doses, timings and the duration of administration.
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Abbreviations
α-SMA α-smooth muscle actin
ADH Alcohol Dehydrogenase
ANGPTL4 Angiopoietin-like 4
ALD Alcoholic Liver Disease
ALT Alanine Aminotransferase
AST Aspartate Aminotransferase
BMI Body Mass Index
CCL Chemokine C-C motif Ligand
CCL4 Carbontetrachloride
CDAA choline-deficient/L-amino acid-defined diet
CDCA chenodeoxycholic acid
CLA Conjugated Linoleic Acid
COX-2 Cyclooxygenase 2
CYP2E1 Cytochrome P450 2E1
Cyp7A1 Cholesterol 7-α hydroxylase 1
DAMPs Damage-Associated Molecular Patterns
DCs Dendritic cells
DEN Diethylnitrosamine
DCA Deoxycholic Acid
ER Endothelial Reticulum
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FFAs Free Fatty Acids
FGF19 Fibroblast Growth Factor 19
FIAF Fating-Induced Adipocyte Factor
FMT Fecal Microbiota Transplantation
FOS Fructo-oligosaccharides
FXR Farnesoid X Receptor
GIT Gastrointestinal Tract
HCC Hepatocellular Carcinoma
HDL High Density Lipoprotein
HFD High Fat Diet
HFGFD High Glucose/Fructose Diet
HOMA-IR Insulin Resistance Index
HSHF High Sucrose and High Fat
HSCs Hepatic Stellate Cells
IFN-γ Interferon-γ
IgA Immunoglobulin A
IL Interleukin
iNOS Inducible nitric oxide synthase
IR Insulin Resistance
JNK Jun N-terminal kinase
LDL Low Density Lipoprotein
LP-F19 Lactobacillus paracasei F19
Lepob/ob Leptin Deficient Mice
LPL Lipoprotein Lipase
LPS Lipopolysaccharides
MBOAT7 Membrane Bound O-acyltransferase Domain-containing 7
MCD Methionine-Choline Deficient Diet
MetS Metabolic Syndrome
miRNAs microRNAs
MMP Metalloproteinases
MTT Microbiota-Targeted Therapy
Myd88 Myeloid differentiation factor 88
NAFLD Nonalcoholic fatty liver disease
NASH Nonalcoholic steatohepatitis
NF-κB Nuclear Factor Kappa-Light-Chain-Enhancer Of Activated B Cells
NLR NOD-like receptors
NO Nitric Oxide
NOD Nucleotide-binding and Oligomerization Domain
PAMPs Pathogen-Associated Molecular Patterns
PNPLA3 Patatin-like Phospholipase Domain-containing 3
PPAR- γ Peroxisome Proliferator-Activated Receptor-γ
qRT-PCR Quantitative Real Time Polymerase Chain Reaction
RCT Randomized Placebo-Controlled Trial
Reg3b Regenerating islet-derived protein 3 b
Reg3g Regenerating islet-derived protein 3 g
ROS Reactive Oxygen Species
rRNA Ribosomal RNA
SASP Senescence-Associated Secretory Phenotype
SCFA Short Chain Fatty Acid
SNPs Single nucleotide polymorphisms
T2DM Type 2 Diabetes Mellitus
TGF- β Transforming growth factor β
TGR5 Takeda G-protein-coupled receptor 5
Th17 T-helper cells 17
TLR Toll-like receptor
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TMAO Trimethylamine N-oxide
TM6SF2 Transmembrane 6 Superfamily Member 2
TNF-α Tumor Necrosis Factor alpha
VLDL Very-Low Density Lipoprotein
UCP-2 UCP-2
WHO/FAO World Health Organization/Food and Agriculture Organization
ZO-1 Zonula Occludens-1
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